Literature DB >> 31838081

Mitochondrial carnitine palmitoyltransferase 2 is involved in Nε-(carboxymethyl)-lysine-mediated diabetic nephropathy.

Jangho Lee1, Ju-Yong Hyon2, Jin Young Min3, Yang Hoon Huh4, Hyo Jung Kim4, Hayoung Lee5, Sung Ho Yun4, Chi-Won Choi6, Su Jeong Ha7, Joon Park8, Young-Ho Chung3, Hye Gwang Jeong9, Sang Keun Ha1, Sung Keun Jung10, YoonSook Kim11, Eun Hee Han12.   

Abstract

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease in the world. Advanced glycation end products (AGEs) are thought to be involved in the pathogenesis of DN via multifactorial mechanisms including the generation of oxidative stress and overproduction of various growth factors and cytokines. AGEs are heterogeneous cross-linked sugar-derived proteins, and Nε-(carboxymethyl)-lysine (CML)-conjugated BSA is a major component of AGEs. However, the proteins involved in DN induction by CML have never been reported. Herein, we investigated specific protein regulators of AGE-mediated DN via proteomic analysis of streptozotocin (STZ)-induced diabetic mice kidneys. We identified 937, 976, and 870 proteins in control, STZ, and STZ + CML-BSA samples, respectively. Bioinformatics analysis identified several CML-mediated proteins potentially involved in kidney damage, activation of fatty acid oxidation (FAO), and mitochondrial dysfunction. Furthermore, we identified the CML-specific differential protein carnitine palmitoyltransferase 2 (CPT2), related to FAO. To confirm the effect of CPT2 and the CML-mediated mechanism, human renal tubular HK-2 cells were treated with CML-BSA and cpt2 siRNA, and examined for FAO-mediated fibrosis and mitochondrial dysfunction. CML-BSA and CPT2 knockdown induced fibrosis-related gene expression and damage to mitochondrial membrane potential. Moreover, CPT2 overexpression recovered CML-induced fibrosis-related gene expression. Based on these results, a decrease in CML-induced CPT2 expression causes mitochondrial FAO damage, leading to renal fibrosis and DN.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Advanced glycation end products; Carnitine palmitoyltransferase 2; Diabetic nephropathy (DN); End-stage renal disease; Mitochondrial dysfunction; N(ε)-(carboxymethyl)-lysine

Mesh:

Substances:

Year:  2019        PMID: 31838081     DOI: 10.1016/j.phrs.2019.104600

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

Review 1.  Mitochondrial Heterogeneity in Metabolic Diseases.

Authors:  Jennifer Ngo; Corey Osto; Frankie Villalobos; Orian S Shirihai
Journal:  Biology (Basel)       Date:  2021-09-17

Review 2.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

Review 3.  Organelle stress and glycation in kidney disease.

Authors:  Reiko Inagi
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

Review 4.  Organelle Stress and Metabolic Derangement in Kidney Disease.

Authors:  Reiko Inagi
Journal:  Int J Mol Sci       Date:  2022-02-02       Impact factor: 5.923

Review 5.  Fatty Acid β-Oxidation in Kidney Diseases: Perspectives on Pathophysiological Mechanisms and Therapeutic Opportunities.

Authors:  Zhumei Gao; Xiangmei Chen
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

6.  Carnosine alleviates diabetic nephropathy by targeting GNMT, a key enzyme mediating renal inflammation and fibrosis.

Authors:  Xue-Qi Liu; Ling Jiang; Lei Lei; Zhen-Yong Nie; Wei Zhu; Sheng Wang; Han-Xu Zeng; Shi-Qi Zhang; Qiu Zhang; Benito Yard; Yong-Gui Wu
Journal:  Clin Sci (Lond)       Date:  2020-12-11       Impact factor: 6.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.